BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

...Themis Bioscience GmbH, which Merck & Co. Inc. (NYSE:MRK) acquired last year.Other portfolio companies include MinervaX ApS...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...University Partners, the University of Florida and the Manning Family FoundationSyndicate backs MinervaX with €47.4MCopenhagen-based MinervaX ApS...
...retina-specificROR2 - Receptor tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated protein 1 Paul Bonanos Vivace Therapeutics Inc. MinervaX ApS Arvinas...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...Pseudomonas aeruginosa and Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza, Entasis Therapeutics Inc., MinervaX ApS...
...open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta Biosystems Ltd. MinervaX ApS Integrated...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza [eds: full name], Entasis Therapeutics Inc., MinervaX ApS...
...open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta Biosystems Ltd. MinervaX ApS Integrated...
BioCentury | Jan 25, 2019
Financial News

Novo's REPAIR fund investments total €18M in 2018

...Denmark) said its REPAIR Impact Fund invested in antibacterial companies Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), MinervaX ApS...
...The fund invested $10 million in Entasis' $75 million September 2018 IPO, €3.6 million in MinervaX...
...Investment in Swiss Antibiotic Company" ). Novo Holdings A/S, Hellerup, Denmark Business: Infectious Sandi Wong Entasis Therapeutics Inc. MinervaX ApS Novo...
BioCentury | Jan 23, 2019
Company News

Management tracks: GSK, A*STAR, Moderna

...fund, which launched in February 2018, made 2018 investments in Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), MinervaX ApS...
BioCentury | Jun 8, 2015
Clinical News

GBS-NN: Phase I started

...GBS-NN with or without an Alhydrogel adjuvant in up to 310 healthy adult female volunteers. MinervaX ApS...
BioCentury | Sep 1, 2014
Company News

Acesion Pharma board of directors update

...Appointed: Ingelise Saunders as chairman, currently a director at Leo Pharma A/S and chairman of MinervaX ApS WIR...
BioCentury | Jan 27, 2014
Financial News

MinervaX completes venture financing

MinervaX ApS , Hellerup, Denmark Business: Infectious Date completed: 1/8/14 Type: Venture financing Raised: DKK3 .5 million ($635,950) Investor: Danish Growth Foundation Note: The financing is a loan. WIR Staff Infectious...
BioCentury | Jan 27, 2014
Financial News

MinervaX completes venture financing

MinervaX ApS , Hellerup, Denmark Business: Infectious Date completed: 1/8/14 Type: Venture financing Raised: DKK18.5 million ($3.4 million) Investors: Novo Seeds; Sunstone Capital; LF Investment WIR Staff Infectious...
Items per page:
1 - 10 of 12
BioCentury | Feb 18, 2021
Finance

With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

...Themis Bioscience GmbH, which Merck & Co. Inc. (NYSE:MRK) acquired last year.Other portfolio companies include MinervaX ApS...
BioCentury | Dec 17, 2020
Finance

Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas

...University Partners, the University of Florida and the Manning Family FoundationSyndicate backs MinervaX with €47.4MCopenhagen-based MinervaX ApS...
...retina-specificROR2 - Receptor tyrosine kinase-like orphan receptor 2YAP1 (YAP) - Yes-associated protein 1 Paul Bonanos Vivace Therapeutics Inc. MinervaX ApS Arvinas...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...Pseudomonas aeruginosa and Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza, Entasis Therapeutics Inc., MinervaX ApS...
...open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta Biosystems Ltd. MinervaX ApS Integrated...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

...Acinetobacter baumannii . REPAIR’s portfolio companies also include Curza [eds: full name], Entasis Therapeutics Inc., MinervaX ApS...
...open to all companies worldwide. Inhua Muijrers-Chen, Associate Editor Novo Holdings A/S Spero Therapeutics Inc. Entasis Therapeutics Inc. Curza Procarta Biosystems Ltd. MinervaX ApS Integrated...
BioCentury | Jan 25, 2019
Financial News

Novo's REPAIR fund investments total €18M in 2018

...Denmark) said its REPAIR Impact Fund invested in antibacterial companies Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), MinervaX ApS...
...The fund invested $10 million in Entasis' $75 million September 2018 IPO, €3.6 million in MinervaX...
...Investment in Swiss Antibiotic Company" ). Novo Holdings A/S, Hellerup, Denmark Business: Infectious Sandi Wong Entasis Therapeutics Inc. MinervaX ApS Novo...
BioCentury | Jan 23, 2019
Company News

Management tracks: GSK, A*STAR, Moderna

...fund, which launched in February 2018, made 2018 investments in Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), MinervaX ApS...
BioCentury | Jun 8, 2015
Clinical News

GBS-NN: Phase I started

...GBS-NN with or without an Alhydrogel adjuvant in up to 310 healthy adult female volunteers. MinervaX ApS...
BioCentury | Sep 1, 2014
Company News

Acesion Pharma board of directors update

...Appointed: Ingelise Saunders as chairman, currently a director at Leo Pharma A/S and chairman of MinervaX ApS WIR...
BioCentury | Jan 27, 2014
Financial News

MinervaX completes venture financing

MinervaX ApS , Hellerup, Denmark Business: Infectious Date completed: 1/8/14 Type: Venture financing Raised: DKK3 .5 million ($635,950) Investor: Danish Growth Foundation Note: The financing is a loan. WIR Staff Infectious...
BioCentury | Jan 27, 2014
Financial News

MinervaX completes venture financing

MinervaX ApS , Hellerup, Denmark Business: Infectious Date completed: 1/8/14 Type: Venture financing Raised: DKK18.5 million ($3.4 million) Investors: Novo Seeds; Sunstone Capital; LF Investment WIR Staff Infectious...
Items per page:
1 - 10 of 12